Cargando…

Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy

OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receivin...

Descripción completa

Detalles Bibliográficos
Autores principales: Suthepwanon, Apisada, Uttasri, Patcharin, Boonyagars, Lakkana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: West Asia Organization for Cancer Prevention 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272631/
https://www.ncbi.nlm.nih.gov/pubmed/35225455
http://dx.doi.org/10.31557/APJCP.2022.23.2.445
_version_ 1784744909092159488
author Suthepwanon, Apisada
Uttasri, Patcharin
Boonyagars, Lakkana
author_facet Suthepwanon, Apisada
Uttasri, Patcharin
Boonyagars, Lakkana
author_sort Suthepwanon, Apisada
collection PubMed
description OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receiving CMT or RT at Vajira Hospital, Navamindradhiraj University, Thailand, from January 1, 2013 to December 31, 2017. Baseline demographic characteristics, HIV disease data, and cancer data were collected. RESULTS: A total of 210 courses of CMT, concurrent chemoradiation therapy (CCRT), or RT treatments were administered to 39 HIV-infected patients with malignancy. Neutropenia occurred in 51 (24.3%) of the 210 treatment courses in 23 (60%) patients. Multivariable analysis revealed that HIV-infected patients with malignancy who received CMT or CCRT (hazard ratio [HR] 10.83, 95% confidence interval [CI] 1.36–86.05, p = 0.024) and those who received over five cycles of CMT (HR 5.25, 95% CI 1.10–26.01, p = 0.037) were independently associated with neutropenia. CONCLUSION: Receiving CMT or CCRT and receiving more than five cycles of CMT are risk factors for neutropenia in HIV-infected patients with malignancy.
format Online
Article
Text
id pubmed-9272631
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher West Asia Organization for Cancer Prevention
record_format MEDLINE/PubMed
spelling pubmed-92726312022-07-14 Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy Suthepwanon, Apisada Uttasri, Patcharin Boonyagars, Lakkana Asian Pac J Cancer Prev Research Article OBJECTIVE: To determine the predictive factors of neutropenia in human immunodeficiency virus (HIV)-infected patients with malignancy receiving chemotherapy (CMT) or radiotherapy (RT). MATERIALS AND METHODS: The author conducted a retrospective study on HIV-infected patients with malignancy receiving CMT or RT at Vajira Hospital, Navamindradhiraj University, Thailand, from January 1, 2013 to December 31, 2017. Baseline demographic characteristics, HIV disease data, and cancer data were collected. RESULTS: A total of 210 courses of CMT, concurrent chemoradiation therapy (CCRT), or RT treatments were administered to 39 HIV-infected patients with malignancy. Neutropenia occurred in 51 (24.3%) of the 210 treatment courses in 23 (60%) patients. Multivariable analysis revealed that HIV-infected patients with malignancy who received CMT or CCRT (hazard ratio [HR] 10.83, 95% confidence interval [CI] 1.36–86.05, p = 0.024) and those who received over five cycles of CMT (HR 5.25, 95% CI 1.10–26.01, p = 0.037) were independently associated with neutropenia. CONCLUSION: Receiving CMT or CCRT and receiving more than five cycles of CMT are risk factors for neutropenia in HIV-infected patients with malignancy. West Asia Organization for Cancer Prevention 2022-02 /pmc/articles/PMC9272631/ /pubmed/35225455 http://dx.doi.org/10.31557/APJCP.2022.23.2.445 Text en https://creativecommons.org/licenses/by-nc/4.0/This work is licensed under a Creative Commons Attribution-Non Commercial 4.0 International License. https://creativecommons.org/licenses/by-nc/4.0/
spellingShingle Research Article
Suthepwanon, Apisada
Uttasri, Patcharin
Boonyagars, Lakkana
Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title_full Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title_fullStr Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title_full_unstemmed Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title_short Predictive Factors of Neutropenia in HIV-Infected Patients with Malignancy Receiving Chemotherapy or Radiotherapy
title_sort predictive factors of neutropenia in hiv-infected patients with malignancy receiving chemotherapy or radiotherapy
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9272631/
https://www.ncbi.nlm.nih.gov/pubmed/35225455
http://dx.doi.org/10.31557/APJCP.2022.23.2.445
work_keys_str_mv AT suthepwanonapisada predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy
AT uttasripatcharin predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy
AT boonyagarslakkana predictivefactorsofneutropeniainhivinfectedpatientswithmalignancyreceivingchemotherapyorradiotherapy